Greenwich LifeSciences, Inc.

NasdaqCM:GLSI Stock Report

Market Cap: US$181.7m

Greenwich LifeSciences Future Growth

Future criteria checks 0/6

Greenwich LifeSciences's earnings are forecast to decline at 0% per annum. EPS is expected to grow by 8.1% per annum.

Key information

-0.003%

Earnings growth rate

8.1%

EPS growth rate

Biotechs earnings growth30.3%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

Low

Last updated22 May 2024

Recent future growth updates

Recent updates

Greenwich LifeSciences: Trying To Move A Needle That Doesn't Like To Budge

Jun 26

Here's Why We're Not Too Worried About Greenwich LifeSciences' (NASDAQ:GLSI) Cash Burn Situation

Jan 12
Here's Why We're Not Too Worried About Greenwich LifeSciences' (NASDAQ:GLSI) Cash Burn Situation

We're Not Very Worried About Greenwich LifeSciences' (NASDAQ:GLSI) Cash Burn Rate

Jan 29
We're Not Very Worried About Greenwich LifeSciences' (NASDAQ:GLSI) Cash Burn Rate

Greenwich LifeSciences: Persevering CEO And Interesting Data

Sep 06

Greenwich LifeSciences halts stock buyback program

Jul 11

Greenwich LifeSciences: A First Look

May 19

Greenwich LifeSciences: Insider Buying And Buybacks Telegraph This Company's Vast Potential

Apr 21

Companies Like Greenwich LifeSciences (NASDAQ:GLSI) Are In A Position To Invest In Growth

Feb 01
Companies Like Greenwich LifeSciences (NASDAQ:GLSI) Are In A Position To Invest In Growth

We Think Greenwich LifeSciences (NASDAQ:GLSI) Can Afford To Drive Business Growth

Sep 30
We Think Greenwich LifeSciences (NASDAQ:GLSI) Can Afford To Drive Business Growth

We're Not Very Worried About Greenwich LifeSciences' (NASDAQ:GLSI) Cash Burn Rate

Apr 04
We're Not Very Worried About Greenwich LifeSciences' (NASDAQ:GLSI) Cash Burn Rate

Are Insiders Buying Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Stock?

Feb 16
Are Insiders Buying Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Stock?

What Is The Ownership Structure Like For Greenwich LifeSciences, Inc. (NASDAQ:GLSI)?

Dec 25
What Is The Ownership Structure Like For Greenwich LifeSciences, Inc. (NASDAQ:GLSI)?

Greenwich LifeSciences: Optimism On 'GP2' Breast Cancer Immunotherapy Candidate

Dec 23

Greenwich LifeSciences under stress on pricing upsized $26.4M equity offering

Dec 18

Greenwich LifeSciences inks deal with Westport Bio for pre-clinical coronavirus vaccine candidates

Dec 15

Greenwich LifeSciences trebles in value as breast cancer therapy shines in mid-stage trial

Dec 09

Earnings and Revenue Growth Forecasts

NasdaqCM:GLSI - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2025N/A-10N/AN/A1
12/31/2024N/A-10N/AN/A1
6/30/2024N/A-10-7-7N/A
3/31/2024N/A-9-7-7N/A
12/31/2023N/A-9-6-6N/A
9/30/2023N/A-9-6-6N/A
6/30/2023N/A-9-6-6N/A
3/31/2023N/A-8-6-6N/A
12/31/2022N/A-8-6-6N/A
9/30/2022N/A-7-6-6N/A
6/30/2022N/A-6-6-6N/A
3/31/2022N/A-6-6-6N/A
12/31/2021N/A-5-4-4N/A
9/30/2021N/A-3-3-3N/A
6/30/2021N/A-3-2-2N/A
3/31/2021N/A-2-2-2N/A
12/31/2020N/A-2-1-1N/A
9/30/2020N/A-100N/A
6/30/2020N/A-100N/A
3/31/2020N/A-400N/A
12/31/2019N/A-300N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: GLSI is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: GLSI is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: GLSI is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if GLSI's revenue is forecast to grow faster than the US market.

High Growth Revenue: GLSI is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if GLSI's Return on Equity is forecast to be high in 3 years time


Discover growth companies